241 results on '"Dybedal, Ingunn"'
Search Results
2. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
3. “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
4. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
5. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders
6. How to manage patients with germline DDX41 variants : Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
7. Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML
8. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
9. Pathogenic DDX41 variants, possible response predictors to low‐dose melphalan in hypo‐ and normocellular MDS and AML
10. MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
11. POSTER: MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
12. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
13. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
14. P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
15. P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
16. Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis In the Registrational, Double-Blind, Placebo Controlled PIONEER Study
17. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
18. Avapritinib versus Placebo in Indolent Systemic Mastocytosis
19. Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo Controlled PIONEER Study
20. Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double Blinded Placebo-Controlled PIONEER Study
21. MPN-274 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
22. Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
23. Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
24. 'Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)'
25. Therapeutic options for CTLA-4 insufficiency
26. Therapeutic options for CTLA-4 insufficiency
27. Therapeutic options for CTLA-4 insufficiency
28. Efficacité et sécurité de l’avapritinib (AVA) chez les patients atteints de mastocytose avancée (AdvSM) : résultats intermédiaires de l’étude PATHFINDER de phase 2
29. Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)
30. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia:Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
31. Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
32. Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B
33. The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Sibling Donors Receiving Peripheral Blood Stem-Cells
34. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
35. Abstract: treatment of patients with myelodysplastic syndromes with G-CSF and erythropoietin
36. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
37. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults:Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
38. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
39. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
40. En mann i 70-årene med ryggsmerter, mageplager og utslett
41. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
42. Tumor necrosis factor (TNF)–mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells
43. Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family
44. MOESM3 of Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
45. Multidisciplinary Management of Mastocytosis : Nordic Expert Group Consensus
46. Multidisciplinary Management of Mastocytosis:Nordic Expert Group Consensus
47. Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
48. Pure Red Cell Aplasia - a New Manifestation of CTLA4 Mutation
49. Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
50. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.